The offering price and number of shares offered were above previous expectations, and Invitae's shares were up around 8 percent in Thursday morning trade.
The company said it plans to offer 3.75 million shares of its common stock and expects to fetch between $11 and $13 per share in its IPO.
The firm plans to offer 5,350,000 shares of its common stock at a price between $13 and $15 per share.
The molecular diagnostics firm anticipates fetching between $12 and $14 per share in its IPO for net proceeds of $52.2 million at the midpoint price of $13 per share.
BGI's spinoff companies, BGI Tech and BGI Dx, have merged and will go public next year.
Invitae offers NGS-based panels for a range of genetic conditions in the fields of cardiology, hereditary cancer, pediatric genetics, neurology, and hematology.
HTG plans to list its shares on the Nasdaq and is the 11th firm this year in the MDx/omics tools space to either go public or file for an IPO.
Pressures, including reimbursements and flat NIH funding, continued to dampen M&A in the past year, but one expert said that the picture may be brighter than it appears.
In an SEC document, the company called current market conditions for an IPO unattractive.
The firm offers a portfolio of genetic tests to help clinicians tailor treatments for patients suffering from cardiovascular disease, neuropsychiatric disorders, and pain.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.